Has Frank Masino received payments from drug or device companies?

Yes. Drug and device makers reported $3,436 in general payments to Frank Masino across 184 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Frank Masino did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Frank Masino come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Frank Masino

Physician Assistant · West Reading, PANPI 1346403748

Payments from drug & device makers

$3,436in general payments, 2019–2025

Across 184 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$1K
Otsuka America Pharmaceutical, Inc.$409
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$362
Neurocrine Biosciences, Inc.$317
Vanda Pharmaceuticals Inc.$220
Johnson & Johnson$207
plus $860 from 13 others

What the payments were for

Food & beverage$3,38999%
Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	63	$1,061
Otsuka America Pharmaceutical, Inc.	23	$409
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	19	$362
Neurocrine Biosciences, Inc.	16	$317
Vanda Pharmaceuticals Inc.	9	$220
Johnson & Johnson	11	$207
Alkermes, Inc.	10	$206
Lundbeck LLC	10	$194
Axsome Therapeutics, Inc.	6	$126
Supernus Pharmaceuticals, Inc.	3	$58
Almatica Pharma LLC	2	$50
E.r. Squibb & Sons, L.L.C.	2	$49
Ironshore Pharmaceuticals Inc.	2	$38
Takeda Pharmaceuticals U.S.A., Inc.	2	$32
Indivior Inc.	2	$32
Corium, LLC	1	$25
Teva Pharmaceuticals USA, Inc.	1	$18
Collegium Pharmaceutical, Inc.	1	$18
Sunovion Pharmaceuticals Inc.	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

VRAYLAR$125

How this compares

$3,436 in reported general payments places this provider in the 90th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$24,098

Medicare patients

Services billed

295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
AustedoDeutetrabenazine	37	$237,563
IngrezzaValbenazine Tosylate	20	$176,452
Invega SustennaPaliperidone Palmitate	51	$146,734
VraylarCariprazine Hcl	83	$118,837
RexultiBrexpiprazole	37	$51,982
Abilify MaintenaAripiprazole	16	$46,600
Aripiprazole	521	$36,762
TrintellixVortioxetine Hydrobromide	58	$34,773
LybalviOlanzapine/Samidorphan Malate	14	$22,850
Quetiapine Fumarate	887	$12,728
Divalproex Sodium ErDivalproex Sodium	171	$12,180
Divalproex Sodium	135	$11,097
Clozapine	90	$7,135
Chlorpromazine Hcl	30	$6,912
Quetiapine Fumarate ErQuetiapine Fumarate	21	$6,509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Loxapine	$18	$240,74550 claims
Neurocrine Biosciences, Inc.Ingrezza	$317	$176,45220 claims
Johnson & JohnsonInvega Sustenna	$207	$146,73451 claims
AbbVieVraylar	$1,061	$118,83783 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena	$409	$98,58253 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix	$32	$34,77358 claims
Alkermes, Inc.Lybalvi	$206	$22,85014 claims
Almatica Pharma LLCSertraline Hcl	$50	$4,265392 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,643 physician assistant providers in Pennsylvania.